Radiation plus adjuvant CCNU (1-[2-chloroethyl]-3cyclohexyl-1-nitrosourea) vs CCNU, hydroxyurea and vincristine in the treatment of malignant glimoa

Mary Costanza, Mary Buechler, John Munzenreider, Bahman Emami, Bijay Mukherji, William Shucart, Michael Scott, Larry Nathanson, Richard Rudders, Bennett Stein, Kalmon Post, Anthony Piro

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Following maximal surgery, 25 patients with malignant glioma were randomized to receive either radiation therapy and CCNU or radiation therapy and CCNU, hydroxyurea, and vincristine. Radiation therapy included 4000 rad to whole brain followed by 1500 rad to the primary. Chemotherapy was either: CCNU alone 130 mg/m2 PO every 6 weeks or triple drug chemotherapy given in 6 week cycles of CCNIJ go mg/m2 PO (one dose), vincristine 1 mg/m2 IV (one dose), and hydroxyurea 1.5 gm/m2 PO every 3 days × 7 doses. Thirteen patients received CCNU alone. Of these, 8 are dead, 2 are alive with progressive disease and 3 are alive with stable disease at 10, 22 and 23 months. Median survival is 10 months. Twelve patients received CCNU, vincristine and hydroxyurea. Of these, 8 are dead, 1 is alive with progressive disease and 3 are stable. Median survival is 9.5 months +. Toxicity included nausea, which was common, leukopenia < 3000 in 7 patients and thrombocytopenia in 9 patients. There were no episodes of bleeding or infection attributable to chemotherapy. Although toxicity was tolerable, no additional benefit could be demonstrated for triple agent chemotherapy with CCNU, vincristine and hydroxyurea compared to CCNU alone. Median survival for both groups was similar at 42-44 weeks.

Original languageEnglish
Pages (from-to)1589-1592
Number of pages4
JournalInternational Journal of Radiation Oncology Biology Physics
Volume5
Issue number9
DOIs
StatePublished - Sep 1979
Externally publishedYes

Keywords

  • CCNU
  • Glioma
  • Hydroxyurea
  • Radiation therapy
  • Vincristine

Fingerprint

Dive into the research topics of 'Radiation plus adjuvant CCNU (1-[2-chloroethyl]-3cyclohexyl-1-nitrosourea) vs CCNU, hydroxyurea and vincristine in the treatment of malignant glimoa'. Together they form a unique fingerprint.

Cite this